CURRENT SCENARIOS AND DRUG DEVELOPMENT STRATEGIES TO MITIGATE DEEP VEIN THROMBOSIS

Abstract

Individuals with deep vein thrombosis are at a higher risk of bleeding and might pass away from pulmonary embolism, a potentially lethal condition. When taking high-dose anticoagulant medicine in clinical therapy, bleeding is always a possibility. Consequently, it becomes crucial that researchers create a specific medication administration mechanism that modulates localised thrombotic lesions while lowering the dose and undesirable adverse reactions. The third most common cause of death that can occur instead of cardiovascular disease is thrombosis in deep veins. It's a clot of blood which typically forms in the deeper leg veins, though it can also affect the cerebral, mesenteric, and arm veins. A serious medical condition that causes the majority of pulmonary emboli is deep-vein thrombosis. Reducing morbidity requires early diagnosis and treatment. The development of an innovative multifunctional drug-loading method is crucial for the proper management of DVT, as it can lengthen treatment duration and enhance therapeutic efficiency.